ALNY Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc (ALNY) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 56% planned / 44% discretionary
Largest single sale: $3.7M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I 5 fills | Director | Sell 10b5-1 | 3,830 | $299.18 | $1.1M | 4,491 −46% of holding | |
| McLaughlin Melissa 5 fills | Chief Human Resources Officer | Sell 10b5-1 | 2,286 | $330.42 | $755.3K | 11,673 −16.4% of holding | |
| McLaughlin Melissa 9 fills | Chief Human Resources Officer | Sell | 1,624 | $319.59 | $519.0K | 13,088 −11% of holding | |
| Garg Pushkal 4 fills | EVP Chief R&D | Sell 10b5-1 | 2,404 | $323.96 | $778.8K | 20,443 −10.5% of holding | |
| Fitzgerald Kevin Joseph 4 fills | CSO & EVP, Head of Research | Sell 10b5-1 | 658 | $323.98 | $213.2K | 21,103 −3% of holding | |
| Greenstreet Yvonne 8 fills | Chief Executive Officer | Sell | 2,933 | $323.08 | $947.6K | 98,493 −2.9% of holding | |
| Poulton Jeffrey V. 8 fills | EVP, Chief Financial Officer | Sell | 2,468 | $323.08 | $797.4K | 64,159 −3.7% of holding | |
| Garg Pushkal 8 fills | EVP Chief R&D | Sell | 2,309 | $323.08 | $746.0K | 23,300 −9% of holding | |
| Tanguler Tolga 8 fills | EVP, Chief Commercial Officer | Sell | 2,309 | $323.08 | $746.0K | 36,500 −5.9% of holding | |
| Fitzgerald Kevin Joseph 8 fills | CSO & EVP, Head of Research | Sell | 633 | $323.08 | $204.5K | 21,831 −2.8% of holding | |
| Garg Pushkal 4 fills | EVP Chief R&D | Sell 10b5-1 | 1,775 | $319.74 | $567.5K | 24,826 −6.7% of holding | |
| Fitzgerald Kevin Joseph 4 fills | CSO & EVP, Head of Research | Sell 10b5-1 | 1,652 | $319.73 | $528.2K | 23,223 −6.6% of holding | |
| Greenstreet Yvonne 10 fills | Chief Executive Officer | Sell | 6,799 | $327.65 | $2.2M | 105,227 −6.1% of holding | |
| Poulton Jeffrey V. 10 fills | EVP, Chief Financial Officer | Sell | 2,206 | $327.65 | $722.8K | 66,414 −3.2% of holding | |
| Garg Pushkal 10 fills | EVP Chief R&D | Sell | 1,717 | $327.66 | $562.6K | 26,848 −6% of holding | |
| Tanguler Tolga 10 fills | EVP, Chief Commercial Officer | Sell | 1,598 | $327.65 | $523.6K | 38,157 −4% of holding | |
| Fitzgerald Kevin Joseph 10 fills | CSO & EVP, Head of Research | Sell | 1,598 | $327.65 | $523.6K | 25,063 −6% of holding | |
| Garg Pushkal 5 fills | EVP Chief R&D | Sell 10b5-1 | 4,627 | $331.34 | $1.5M | 26,629 −14.8% of holding | |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell 10b5-1 | 2,041 | $331.96 | $677.5K | 21,264 −8.8% of holding | |
| Greenstreet Yvonne | Chief Executive Officer | Sell | 6,958 | $310.08 | $2.2M | 85,662 −7.5% of holding | |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,242 | $310.08 | $695.2K | 59,802 −3.6% of holding | |
| Garg Pushkal | EVP Chief R&D | Sell | 2,242 | $310.08 | $695.2K | 24,848 −8.3% of holding | |
| Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 1,959 | $310.08 | $607.4K | 31,769 −5.8% of holding | |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 1,959 | $310.08 | $607.4K | 23,305 −7.8% of holding | |
| Fitzgerald Kevin Joseph 6 fills | CSO & EVP, Head of Research | Sell 10b5-1 | 2,290 | $370.33 | $848.1K | 23,357 −8.9% of holding | |
| Greenstreet Yvonne 21 fills | Chief Executive Officer | Sell | 9,577 | $362.86 | $3.5M | 87,741 −9.8% of holding | |
| Poulton Jeffrey V. 21 fills | EVP, Chief Financial Officer | Sell | 2,780 | $362.87 | $1.0M | 60,173 −4.4% of holding | |
| Garg Pushkal 21 fills | EVP Chief R&D | Sell | 1,510 | $362.87 | $547.9K | 23,982 −5.9% of holding | |
| Tanguler Tolga 21 fills | EVP, Chief Commercial Officer | Sell | 1,510 | $362.87 | $547.9K | 31,199 −4.6% of holding | |
| Fitzgerald Kevin Joseph 21 fills | CSO & EVP, Head of Research | Sell | 1,510 | $362.87 | $547.9K | 25,025 −5.7% of holding | |
| Fitzgerald Kevin Joseph 11 fills | CSO & EVP, Head of Research | Sell 10b5-1 | 12,128 | $452.18 | $5.5M | 25,224 −32.5% of holding | |
| Greenstreet Yvonne 9 fills | Chief Executive Officer | Sell 10b5-1 | 10,000 | $451.27 | $4.5M | 74,755 −11.8% of holding | |
| Greenstreet Yvonne 11 fills | Chief Executive Officer | Sell 10b5-1 | 15,650 | $453.69 | $7.1M | 80,348 −16.3% of holding | |
| Garg Pushkal 5 fills | EVP Chief R&D | Sell 10b5-1 | 3,022 | $451.48 | $1.4M | 22,561 −11.8% of holding | |
| Greenstreet Yvonne 12 fills | Chief Executive Officer | Sell | 8,924 | $452.05 | $4.0M | 73,983 −10.8% of holding | |
| Poulton Jeffrey V. 12 fills | EVP, Chief Financial Officer | Sell | 3,821 | $452.05 | $1.7M | 57,723 −6.2% of holding | |
| Garg Pushkal 12 fills | EVP Chief R&D | Sell | 2,937 | $452.05 | $1.3M | 26,065 −10.1% of holding | |
| Fitzgerald Kevin Joseph 12 fills | CSO & EVP, Head of Research | Sell | 2,441 | $452.05 | $1.1M | 27,576 −8.1% of holding | |
| Tanguler Tolga 12 fills | EVP, Chief Commercial Officer | Sell | 1,405 | $452.05 | $635.1K | 28,788 −4.7% of holding | |
| Reitan Colleen F 16 fills | Director | Sell 10b5-1 | 18,000 | $467.60 | $8.4M | 17,130 −51.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.